The goal of this clinical trial is to demonstrate the superiority of remote monitoring with the Bora Care solution in patients with COPD and frequent exacerbations (experimental group) compared to conventional follow-up alone (control group) on the total number of hospital days per patient for respiratory deterioration over 12 months of follow-up. The main question it aims to answer is: Does remote monitoring of COPD patients reduce the average annual length of hospitalization for exacerbations of COPD patients? All participants will benefit a conventional clinical follow-up. Participants in experimental group will also benefit from the Bora care remote monitoring system.
Control group (control): conventional follow-up For the target population (frequent exacerbating COPD patients), the usual follow-up includes two consultations with the general practitioner and one consultation with the pulmonologist per year. The inclusion and follow-up visit at 12 months by a pulmonologist are consistent with the follow-up of COPD patients in current practice and the recommendations of HAS (National Authority for Health) and SPLF (French-Language Society of Pneumology). Experimental group (conventional monitoring + remote monitoring): The patients will be subject to conventional clinical follow-up and at the same time benefit from the Bora care remote monitoring system. The Bora care remote monitoring system includes a BoraBand wristband measuring vital signs at home, the Bora Connect platform for caregiver visualization of data and the BVS3 score for early detection of COPD exacerbations. Patients are monitored daily remotely by Case Managers (nurses trained in Bora Care solution), who, when the BVS3 \> 3 alert is triggered on Bora Connect, call the patient to inform the patient about his symptoms, then alert the pulmonologist by transmitting the information from Bora Connect and the minutes of the phone call, who, according to conventional management, decides whether or not to hospitalize the patient, or to generate an unscheduled consultation in order to prescribe drug treatment, and/or to prescribe additional examinations, and/or to adapt the patient's oxygen therapy prescription. The Case Manager re-evaluates the situation after 48 hours and 96 hours if necessary and forwards the information to the pulmonologist. The nature of the transmission of information (telephone or email) between the Case Manager and the pulmonologist in case of an alert is defined when the patient is included by the pulmonologist. If desired, remotely monitored patients will be able to access the Bora Connect interface provided for patients (restricted viewing of data).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
380
Bora Band wristband measuring vital signs at home, Bora Connect platform for caregiver visualization and BVS3 early detection of COPD exacerbations
CHU de Brest
Brest, Brittany Region, France
RECRUITINGCentre Hospitalier Bretagne Atlantique
Vannes, Brittany Region, France
RECRUITINGCentre Hospitalier de Chartres
Le Coudray, Centre-Val de Loire, France
NOT_YET_RECRUITINGCentre Hospitalier Verdun
Verdun, Grand Est, France
NOT_YET_RECRUITINGGroupement des Hôpitaux de l'Institut Catholique de Lille (GHICL)
Lille, Hauts-de-France, France
NOT_YET_RECRUITINGClinique du Millénaire
Montpellier, Occitanie, France
NOT_YET_RECRUITINGCentre Hospitalier Universitaire de Toulouse
Toulouse, Occitanie, France
NOT_YET_RECRUITINGHôpital Européen Marseille
Marseille, Provence-Alpes-Côte d'Azur Region, France
NOT_YET_RECRUITINGHôpital de la Pitié Salpêtrière - AP-HP
Paris, Île-de-France Region, France
NOT_YET_RECRUITINGHôpital Cochin - AP-HP
Paris, Île-de-France Region, France
RECRUITINGDemonstrate the superiority of remote monitoring with the Bora Care solution in patients with COPD and frequent exacerbations compared to conventional follow-up.
Number of hospital days for respiratory deterioration per patient over 12 months.
Time frame: 1 year
Evaluate the effect of the device on the number of hospitalizations per patient.
Number of hospitalizations within 12 months of implementation of Bora Care remote monitoring.
Time frame: 1 year
Evaluate the effect of the device on the average length of stay.
Average length of stay in hospital within 12 months of the implementation of Bora Care.
Time frame: 1 year
Assess the overall quality of life of patients at baseline and at the end of the trial. (1)
Score from CAT (Chronic Obstructive Pulmonary Disease Assessment Test) questionnaire to assess the quality of life collected at Day 0, M6, M12.
Time frame: 1 year
Assess the overall quality of life of patients at baseline and at the end of the trial. (2)
Score from Short Form 36 (SF36) quality of life assessment questionnaire to assess the quality of life collected at Day 0, M6, M12.
Time frame: 1 year
Assess the overall quality of life of patients at baseline and at the end of the trial. (3)
Score from EXACT E-RS (Evaluating Respiratory Symptoms) symptom assessment questionnaire to assess the quality of life collected at Day 0, M6, M12.
Time frame: 1 year
Assess the conformity of use of the Bora Care device.
Number of hours spent wearing the Bora Connect bracelet normalized by the total number of hours spent in the remote monitoring session, information collected via the Bora Care tool.
Time frame: 3 years
Assess the impact of the device on the organisation of care. (1)
Number and nature of emergency, resuscitation, consultations and teleconsultations with the pulmonologist or attending physician.
Time frame: 3 years
Assess the impact of the device on the organisation of care. (2)
Duration of emergency, resuscitation, consultations and teleconsultations with the pulmonologist or attending physician.
Time frame: 3 years
Assess the impact of the device on the organisation of care. (3)
Number and nature of follow-up examinations and new pathologies detected during follow-up.
Time frame: 3 years
Assess the impact of the device on the quality of support. (1)
Number and nature of prescribed pharmacological treatments and prescribed oxygen therapy.
Time frame: 3 years
Assess the impact of the device on the quality of support. (3)
Duration of prescribed pharmacological treatments and prescribed oxygen therapy.
Time frame: 3 years
Assess patient and caregiver satisfaction with the device. (1)
Subjective assessment by the patient of the device, the reassurance provided by the device, the assistance to resume physical activity provided by the device, obtained using satisfaction questionnaires at M6 and M12.
Time frame: 1 year
Assess patient and caregiver satisfaction with the device. (2)
Subjective assessment by the patient of the overall quality of follow-up obtained using a detailed questionnaire (Likert scale) and an open-ended question about possible improvements at M6 and M12.
Time frame: 1 year
Assess patient and caregiver satisfaction with the device. (3)
Subjective assessment by caregivers of the Bora Care solution's impact on patient care using questions about organizational impacts and improved quality of care provided by the device, obtained using a satisfaction questionnaire at M6 and M12.
Time frame: 1 year
Evaluate the performance of the warning device in the early detection of exacerbations.
The number and nature of the alerts issued by the Bora Care solution, the number and nature of the actions taken following the alert specified in the alert management tool in the Bora Connect tool.
Time frame: 3 years
Identify new markers of exacerbations or other clinical events.
Alert performance in detecting exacerbations and other medical events by calculating alert sensitivity and specificity.
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.